<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336165">
  <stage>Registered</stage>
  <submitdate>29/10/2010</submitdate>
  <approvaldate>9/11/2010</approvaldate>
  <actrnumber>ACTRN12610000962033</actrnumber>
  <trial_identification>
    <studytitle>The effect of curcumin on paraproteinemia and bone turnover in patients with monoclonal gammopathy of undefined significance (MGUS) and indolent myeloma.</studytitle>
    <scientifictitle>The effect of curcumin on paraproteinemia and bone turnover in patients with monoclonal gammopathy of undefined significance (MGUS) and indolent myeloma.</scientifictitle>
    <utrn>nil</utrn>
    <trialacronym>nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>myeloma</healthcondition>
    <healthcondition>cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Myeloma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>curcumin - complementary medicine. patients will be administered either 4g curcumin or 4g placebo per day at the start of  the study. After 3 months they will be crossed over for a futher 3 months. There is no wash-out period. The curcumin is being administered as stick-packs of granules.</interventions>
    <comparator>placebo composed of FD&amp;C yellow 6, riboflavin and non-pareil seeds (pharma grade sugar and starch)</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>decrease in abnormal protein as determined by serum assay.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>decrease in bone turnover as determined by serum assay and urine analysis.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>significant paraproteinemia as defined by a serum M-protein value of equal to or greater than 18g/L.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>other malignancies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Blood tests will determine whether a patient has  MGUS or indolent myeloma. Allocation concealment is being done by numbered containers.</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>27/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St George Hospital</primarysponsorname>
    <primarysponsoraddress>Gray street, Kogarah, NSW, 2217</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St George Hospital</fundingname>
      <fundingaddress>Gray street 
Kogarah
nsw
2217</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Due to the results of previous studies both in vivo and in vitro, we hypothesised that curcumin may decrease paraproteinemia and bone turnover in MGUS and indolent myeloma patients. A pilot study conducted by us showed a reduction in paraprotein levels and the uNTX bone turnover marker in a select group of MGUS patients. This trial is a continuation of the pilot study and we aim to prove that curcumin may act to prevent the progression of MGUS to active myeloma.</summary>
    <trialwebsite>nil</trialwebsite>
    <publication>Golombick et al. The potential role of curcumin in patients with MGUS - its effect on paraproteinemia and the urinary N-telopeptide of type 1 collagen bone turnover marker. Clin Cancer Res 2009;15(18) 2009</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Sydney Illawara Human Research Ethics Committee</ethicname>
      <ethicaddress>St George Hospital, Gray street, Kogarah, NSW, 2217</ethicaddress>
      <ethicapprovaldate>2/12/2008</ethicapprovaldate>
      <hrec>07/03 Diamond</hrec>
      <ethicsubmitdate>19/11/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Terry Golombick</name>
      <address>level 3
Prichard Wing
St George Hospital
Gray street
Kogarah
NSW</address>
      <phone>+61 2 91132767</phone>
      <fax>+61 2 91133966</fax>
      <email>terry.golombick@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Terry Golombick</name>
      <address>level 3
Prichard Wing
St George Hospital
Gray street
Kogarah
NSW
2217</address>
      <phone>+61 2 91132767</phone>
      <fax>+61 2 91133966</fax>
      <email>terry.golombick@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Terry Golombick</name>
      <address>Prichard Wing
St George Hospital
Gray street 
Kogarah
NSW
2217</address>
      <phone>+61 2 91132767</phone>
      <fax>+61 2 91133966</fax>
      <email>terry.golombick@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>